Abstract:Over recent years, the debate has intensified on whether multiple sclerosis (MS) is primarily an autoimmune disorder or a neurodegenerative condition. The recent proposal of an alternative “inside out” model1 reflects the growing unease with the “EAE-like” scenario (the “outside in” model) as the traditional explanation for MS. Still, even in this new model, MS is seen as the result of an “immunological convolution” between the proposed primary neurodegenerative defect, and an “aberrant immune response” that would be the result of it. Both the traditional “outside in” and the newly proposed “inside out” model of MS thus continue to make the assumption that people with MS have an abnormal autoimmune response. In my view, there is no good reason for this. For decades, the MS research community has tried to clarify which T cells would be involved in the attack on a seemingly innocent central nervous system (CNS) in people with MS, and which myelin antigen(s) would be their target. Yet, as early as 1984, Lisak and colleagues already concluded that “there is no proof of either antibody and/or cell-mediated hypersensitivity to any single identifiable CNS constituent whether a constituent of normal CNS or specific to the CNS of MS patients”.2 In the 30 years that have passed since, the research community has not been able to come up with any solid and reproducible evidence to argue differently. With regard to its reactivity to myelin, or any other CNS constituent, the immune system of people with MS is essentially indistinguishable from that in healthy subjects. The remarkable persistence of the idea that abnormal autoimmunity exists in MS patients is likely explained by the convenience with which it seems to clarify two key features of MS, that is, the migration of peripheral T cells into the CNS, and the tissue specificity of the inflammatory process. Activated T cells migrate across the blood–brain barrier more readily than resting cells, and their specificity for myelin antigens would explain why only myelinated axons are targeted. Yet, both features can also be explained in another way. I propose that the interplay between two key molecules, interferon-gamma (IFN-γ) and the small heatshock protein HSPB5 (formerly known as αB-crystallin) offers an alternative. IFN-γ has potentially detrimental effects when it is released within the CNS. It promotes classical activation of microglia and macrophages, enhancing phagocytosis and tissue destruction by these cells. This effect is particularly prominent when macrophage-like cells are simultaneously activated by a Toll-like receptor (TLR) agonist that induces TNF-α release.3 Even when such an agonist on its own would promote beneficial regulatory responses, exposure to IFN-γ reprograms macrophages and microglia to shift to a state of classical activation. TLR-mediated production of IL-10 collapses, and that of TNF-α, IL-1β, IL-6 and IL-12 strongly increases. Furthermore, IFN-γ synergizes with TNF-α and IL-1β in activating blood–brain barrier endothelial cells.4 Together with the release of several chemokines by classically activated microglia and macrophages, this strongly promotes leukocyte recruitment into the CNS. Thirdly, IFN-γ kills oligodendrocyte progenitor cells, and in this way subverts the process of remyelination.5 As also recently evidenced by the close association between IFNγ and TNF-α with cortical demyelination in secondary progressive MS,6 release of IFN-γ within the CNS thus poses considerable risks, especially when an additional TLR agonist acting on microglia is around as well. The role of HSPB5 in the interplay could readily explain the tissue specificity of the disease process in MS. HSPB5 is a stress-inducible CNS-borne TLR2 agonist. As reviewed by us previously,7 HSPB5 occasionally accumulates in oligodendrocytes and myelin in MS brains to unusually high levels, not seen in other neurodegenerative disorders. Although the trigger for this phenomenon remains to be clarified, HSPB5 selectively accumulates in groups of stressed or apoptotic oligodendrocytes within the clusters of activated microglia that are found in macroscopically normal-appearing tissue, even prior to demyelination and obvious leukocyte infiltration.8 This occurs in early relapsing as well as in late progressive forms of Autoimmunity in multiple sclerosis need not be abnormal

EP11.03-41 Successful Treatment with Pembrolizumab Alone for SMARCA4-deficient Lung Sarcomatoid with a High-TMB and PD-L1(+) A Case Report

Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report

Autoimmunity in multiple sclerosis need not be abnormal

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer

Concurrent EGFR mutation and SMARCA4 deficiency in non-small cell lung cancer: A case report and literature review

Extremely Rapid Response to Pembrolizumab in a SMARCA4 Mutant PD-L1 Highly Expressive Advanced Lung Adenocarcinoma: A Case Report

Thoracic SMARCA4-deficient Undifferentiated Tumor-Pathological Diagnosis and Com-Bined Immune Checkpoint Inhibitor Treatment

[Thoracic SMARCA4-deficient undifferentiated tumor-pathological diagnosis and combined immune checkpoint inhibitor treatment]

Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review

Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods

Response to PD-1 inhibitor in SMARCB1‐deficient undifferentiated rectal carcinoma with low TMB, proficient MMR and BRAF V600E mutation: a case report and literature review

A case of surgically treated non-metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review

The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation

Promising Efficacy of Immune-Checkpoint Inhibitor with Chemotherapy for SMARCA4-deficient Thoracic Sarcomatoid Tumors.

KEYNOTE-158: Final Analysis of Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-High/mismatch Repair Deficient Advanced Solid Tumors.

Pembrolizumab Plus Chemotherapy for Chinese Patients with Metastatic Squamous NSCLC in KEYNOTE-407

SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy

SMARCA4: Current status and future perspectives in non-small-cell lung cancer

Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines.

An aggressive case of a thoracic undifferentiated SMARCA4‐deficient tumor with extensive pleural involvement